0000000000303315

AUTHOR

D. Boehm

showing 9 related works from this author

Immunoglobulin Kappa C Has Independent Prognostic Significance in Node-Negative Breast Cancer.

2009

Abstract Background: Utilizing microarray based gene-expression analysis of fresh-frozen tissue we could recently demonstrate the prognostic impact of a B cell metagene in node-negative breast cancer (Cancer Res 68: 5405-5413, 2008). In the present study we investigated the prognostic significance of immunoglobulin kappa c (IGKC) in formalin-fixed paraffin embedded (FFPE) breast cancer specimens of 363 node-negative breast cancer patients which were not treated in the adjuvant setting.Methods: RT-PCR was used to analyze mRNA expression of IGKC in FFPE tissue of 363 patients with node-negative breast cancer. Additionally to IGKC we examined the prognostic impact of age, histological grade, t…

OncologyCancer Researchmedicine.medical_specialtyUnivariate analysisPathologyMicroarraybusiness.industrymedicine.medical_treatmentEstrogen receptorCancermedicine.diseaseBreast cancermedicine.anatomical_structureOncologyInternal medicineProgesterone receptormedicinebusinessAdjuvantB cellCancer Research
researchProduct

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis

2018

Abstract Background Ki-67 is a marker of proliferating cells; in this meta-analysis we aimed to examine whether Ki-67 expression can predict recurrence rates of breast ductal carcinoma in situ (DCIS). Materials and Methods This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to April 30, 2017. Random effects (DerSimonian–Laird) models were used for the calculation of pooled relative risk (RR) estimates; meta-regression analysis was also performed. Separate analyses were performed according to Ki-67 expression cutoff levels, invasiveness of recurrence,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsRisk Assessment03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansMeta-regressionBreastMastectomybiologybusiness.industryDuctal carcinomaPrognosismedicine.diseaseConfidence intervalCarcinoma Intraductal NoninfiltratingKi-67 Antigen030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMeta-analysisKi-67biology.proteinFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCohort studyClinical Breast Cancer
researchProduct

Prognostic significance of the chemokine CXCL13 in node-negative breast cancer

2013

615 Background: The chemokine CXCL13 is chemotactic for B cells. We examined the prognostic significance of CXCL13 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for CXCL13 (205242_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of CXCL13 on metastasis-free survival (MFS) was examined in the whole cohort and in different molecular subtypes (ER+/HER2-, ER-/HER2-, HER2+). Independent prognostic relevance was a…

OncologyCancer Researchmedicine.medical_specialtyChemokineMicroarraybiologybusiness.industryMrna expressionObstetrics and GynecologyChemotaxismedicine.diseaseNode negativeBreast cancerOncologyInternal medicineMaternity and MidwiferyImmunologyCancer researchbiology.proteinMedicineCXCL13businessGeburtshilfe und Frauenheilkunde
researchProduct

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St G…

2009

Background: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. Patients and methods: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age 2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). Results: The Node-…

AdultTime FactorsBreast NeoplasmsKaplan-Meier EstimateRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalBreast cancerBreast cancer 3Predictive Value of TestsMedicineHumansLongitudinal StudiesProspective StudiesRisk factorAgedNeoplasm StagingRetrospective StudiesAged 80 and overNeovascularization Pathologicbusiness.industryHazard ratioCancerRetrospective cohort studyHematologyGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisTreatment OutcomeOncologyAdult; Aged; Aged 80 and over; Algorithms; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Breast Neoplasms/radiotherapy; Breast Neoplasms/surgery; Disease-Free Survival; Female; Follow-Up Studies; Genes erbB-2; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neovascularization Pathologic; Predictive Value of Tests; Prognosis; Prospective Studies; Receptors Progesterone/analysis; Regression Analysis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Time Factors; Treatment OutcomeMultivariate AnalysisRegression AnalysisFemaleBreast diseasebusinessRisk assessmentReceptors ProgesteroneAlgorithmAlgorithmsFollow-Up Studies
researchProduct

Reproduction beyond cancer: A message of hope for young women

2006

Abstract Objective. Aggressive chemotherapy and radiotherapy or radical oncological surgery in young women with cancer has greatly enhanced these patients' life expectancy, but these treatments often cause infertility or premature ovarian failure due to a massive destruction of the ovarian reserve. The objective of this review is to discuss the effect of the various cancer treatments on fertility and present the various fertility sparing operations and fertility preservation strategies. Method. An extensive survey of the most up-to-date literature was performed. Results. This review discusses the impact of current cancer treatment on fertility potential and the various surgical and assisted…

Infertilitymedicine.medical_specialtyGenital Neoplasms Femalemedia_common.quotation_subjectmedicine.medical_treatmentBreast NeoplasmsFertilitymedicineHumansFertility preservationIntensive care medicineOvarian reservemedia_commonGynecologybusiness.industryObstetrics and GynecologyCancermedicine.diseaseCombined Modality TherapyPremature ovarian failureRadiation therapyFertilityOncologyLife expectancyFemalebusinessInfertility FemaleGynecologic Oncology
researchProduct

Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer

2012

Background: Biomarkers of the immune system are currently not used as prognostic factors in breast cancer. We analyzedthe association of the B cell/plasma cell marker immunoglobulin kappa C (IGKC) and survival of untreated node-negative breast cancer patients.Material and Methods: IGKC expression was evaluated by immunostaining in a cohort of 335 node-negative breast cancer patients with a median follow-up of 152 months. The prognostic significance of IGKC for disease-free survival (DFS) and breast cancer-specific overall survival (OS) was evaluated with Kaplan-Meier survival analysis as well as univariate and multivariate Cox analysis adjusted for age at diagnosis, pT stage, histological g…

OncologyPathologyB CellsEpidemiology610 MedizinEstrogen receptorlcsh:MedicineMetastasis610 Medical sciencesBasic Cancer ResearchPathologyStage (cooking)lcsh:ScienceUnivariate analysisMultidisciplinaryHazard ratioObstetrics and GynecologyMiddle AgedImmunohistochemistryOncologyMedicineFemaleResearch Articlemedicine.medical_specialtyImmune CellsImmunoglobulinsBreast NeoplasmsDisease-Free SurvivalImmunoglobulin kappa-ChainsBreast cancerDiagnostic MedicineInternal medicineProgesterone receptorBreast CancermedicineHumansAntibody-Producing CellsSurvival analysisImmune Evasionbusiness.industrylcsh:RImmunitymedicine.diseaseConfidence intervalBiomarker EpidemiologyHumoral Immunitylcsh:QClinical ImmunologybusinessBiomarkersGeneral Pathology
researchProduct

Prediction of late metastasis in node-negative breast cancer.

2012

10551 Background: Prediction of late metastasis is of clinical relevance in breast cancer. However, systematic genome-wide studies to identify genes associated with increased risk of metastasis 5 or more years after surgery are scarce. Methods: We examined the natural course of disease in three previously published cohorts (Mainz, Rotterdam, Transbig) including 766 node-negative breast cancer patients with gene array data who did not receive systemic chemotherapy in the adjuvant setting. We established a Cox regression based method adjusted for multiple testing that identified genes predicting late metastasis (5 or more years after surgery). Only those genes were accepted that showed simil…

CA15-3OncologyCancer Researchmedicine.medical_specialtybusiness.industryCancermedicine.diseaseMetastasisNode negativeBreast cancerIncreased riskOncologyInternal medicinemedicineClinical significancebusinessJournal of Clinical Oncology
researchProduct

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer

2008

Abstract Purpose: Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention not only as a prognostic factor in breast cancer but also as a potential target for immunotherapy. We examined Ep-CAM expression in 402 consecutive node-negative breast cancer patients with long-term follow-up not treated in the adjuvant setting. Experimental Design: Ep-CAM expression was evaluated by immunostaining. Its prognostic effect was estimated relative to overexpression/amplification of HER-2, histologic grade, tumor size, age, and hormone receptor expression. Results: Ep-CAM status was positive in 106 (26.4%) patients. In multivariate analysis, Ep-CAM status was associated with disea…

AdultOncologyCancer ResearchPathologymedicine.medical_specialtyNeoplasms Hormone-DependentEstrogen receptorBreast Neoplasmschemistry.chemical_compoundDrug Delivery SystemsBreast cancerAntigens NeoplasmInternal medicineProgesterone receptorBiomarkers TumormedicineHumansAgedAged 80 and overbusiness.industryHazard ratioCancerEpithelial cell adhesion moleculeMiddle AgedEpithelial Cell Adhesion MoleculePrognosismedicine.diseaseOncologychemistryHormone receptorLymphatic MetastasisFemaleBreast diseasebusinessCell Adhesion MoleculesClinical Cancer Research
researchProduct

Quality of life and adjuvant tamoxifen treatment in breast cancer patients

2009

About two-thirds of all breast cancer patients are treated with adjuvant hormonal therapy. Side effects of tamoxifen and their effects on physical, emotional and social functioning have been shown to impair the quality of life. Aim of this paper was to evaluate the side effects and level of influence on the physical, emotional and social functioning caused by tamoxifen treatment. For assessment of quality of life an own questionnaire was designed. Between January 2001 and December 2003, 136 women with breast cancer and adjuvant tamoxifen therapy were included in this study. Data of side effects, physical and mental health and patients' self-evaluation identified detrimental effects on patie…

AdultOncologymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBreast NeoplasmsBreast cancerQuality of lifeSurveys and QuestionnairesInternal medicineBody ImagemedicineHumansskin and connective tissue diseasesAgedAged 80 and overChemotherapyAdjuvant tamoxifenbusiness.industryMiddle Agedmedicine.diseaseMental healthTamoxifenOncologyChemotherapy AdjuvantQuality of LifeHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugEuropean Journal of Cancer Care
researchProduct